Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

@article{Palumbo2008OralMP,
  title={Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.},
  author={Antonio Palumbo and Sara Bringhen and Anna Marina Liberati and Tommaso Caravita and Antonietta Pia Falcone and Vincenzo Callea and Marco Montanaro and Roberto Ria and Antonio Capaldi and Renato Zambello and Giulia Benevolo and Daniele Derudas and Fausto Dore and Federica Cavallo and Francesca Gay and Patrizia Falco and Giovannino Ciccone and Pellegrino Musto and Michele Cavo and Mario Boccadoro},
  journal={Blood},
  year={2008},
  volume={112 8},
  pages={
          3107-14
        }
}
The initial analysis of the oral combination melphalan, prednisone, and thalidomide (MPT) in newly diagnosed patients with myeloma showed significantly higher response rate and longer progression-free survival (PFS) than did the standard melphalan and prednisone (MP) combination and suggested a survival advantage. In this updated analysis, efficacy and safety end points were updated. Patients were randomly assigned to receive oral MPT or MP alone. Updated analysis was by intention to treat and… Expand

Paper Mentions

Interventional Clinical Trial
Aim of this study is to evaluate Daratumumab effect on MRD-positive patients with Multiple Myeloma (MM) who achieved >VGPR after any therapy (ASCT, VMP, Rev-Dex). Daratumumab 16 mg/kg… Expand
ConditionsMyeloma Multiple
InterventionDrug
Interventional Clinical Trial
To evaluate: - the incidence of venous thromboembolic event (VTE) - the incidence of hemorrhagic complications, In a population of patients with myeloma who… Expand
ConditionsMyeloma, Venous Thromboembolism
InterventionDrug
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant
TLDR
The results show an improved activity of MPT at a cost of increased toxicity, and it is believed that MPT can be considered one of the new standard of care for elderly or transplant-ineligible patients with MM. Expand
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma – a retrospective population based study of 1162 patients
TLDR
Treatment with MPT gave a significantly better OS rate after both first and second line of therapy when compared with treatment with MP only, and the relative risk for death in the MPT group vs. the MP group was significantly lower. Expand
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis
TLDR
In previously untreated, transplant ineligible, elderly myeloma patients, the addition of T to MP results in significantly improved RR and PFS with a trend towards improvement in OS compared with MP alone, but at a cost of significantly greater toxicity. Expand
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group
TLDR
Although patients treated with MPT were relatively younger and had more frequent RI, better responses and less early mortality were observed in all age groups despite more frequent discontinuation. Expand
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.
TLDR
It is concluded that thalidomide added to MP improves OS and PFS in previously untreated elderly patients with multiple myeloma, extending the median survival time by on average 20%. Expand
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
TLDR
It is demonstrated that thalidomide improves the response rate and VGPR in elderly patients with newly diagnosed MM and MP-T also results in a better EFS, PFS, and OS. Expand
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
  • C. Hulin, T. Facon, +17 authors P. Moreau
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
This trial confirms the superiority of the combination melphalan and prednisone plus thalidomide over melphAlan andprednisone alone for prolonging survival in very elderly patients with newly diagnosed myeloma. Expand
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
TLDR
MPT had a significant antimyeloma effect, but this did not translate into improved survival, and most quality of life outcomes improved equally in both arms, apart from constipation, which was markedly increased in the MPT arm. Expand
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
TLDR
VMP significantly prolongs OS versus MP after lengthy follow-up and extensive subsequent antimyeloma therapy, and appears more beneficial than first treating with conventional agents and saving bortezomib- and other novel agent-based treatment until relapse. Expand
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.
TLDR
Overview analysis demonstrated that thalidomide maintenance was associated with a significant late OS benefit, and iFISH testing is important in assessing the clinical impact of maintenance therapy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 24 REFERENCES
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
TLDR
Oral MPT is an effective first-line treatment for elderly patients with multiple myeloma and anticoagulant prophylaxis reduces frequency of thrombosis. Expand
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
TLDR
In elderly patients ineligible for transplantation, the combination of bortezomib plus MP appears significantly superior to MP, producing very high CR rates, including immunophenotypic CRs, even in patients with poor prognostic features. Expand
Melphalan-Prednisone-Thalidomide (MP-T) Demonstrates a Significant Survival Advantage in Elderly Patients ≥75 Years with Multiple Myeloma Compared with Melphalan-Prednisone (MP) in a Randomized, Double-Blind, Placebo-Controlled Trial, IFM 01/01.
TLDR
The results confirm the superiority of MP-T over MP for prolonging OS in elderly patients with newly diagnosed MM and a new era of progress is opened for these very elderly patients. Expand
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
  • A. Palumbo, P. Falco, +15 authors M. Petrucci
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
Oral MPR therapy is a promising first-line treatment for elderly myeloma patients and aspirin appears to provide adequate antithrombosis prophylaxis. Expand
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial
TLDR
The results of this trial provide strong evidence to indicate that the use of thalidomide in combination with melphalan and prednisone should, at present, be the reference treatment for previously untreated elderly patients with multiple myeloma. Expand
Melphalan-Prednisone-Thalidomide to Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled Randomised Phase 3 Trial.
TLDR
Previously untreated patients with multiple myeloma were included in this double-blind randomised trial and overall survival, event free survival, response, time to progression and quality of life were met. Expand
Thalidomide for treatment of multiple myeloma: 10 years later.
TLDR
In elderly, newly diagnosed patients, 3 independent randomized studies have reported that the oral combination of melphalan and prednisone plus thalidomide (MPT) is better than the standard melphAlan and predisonsone (MP) and 2 have shown improved overall survival for patients assigned to MPT. Expand
Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.
TLDR
Fifty patients with multiple myeloma >or=75 years of age received primary treatment with melphalan, dexamethasone, and thalidomide, repeated every 5 weeks for three courses, achieving a partial response and 10% a complete response. Expand
Melphalan and its role in the management of patients with multiple myeloma
TLDR
Thalidomide, its immunomodulatory derivative lenalidomides and the proteasome inhibitor bortezomib, in combination with oral melphalan in the elderly and with intravenous melphAlan in younger patients, are changing the traditional treatment paradigm of multiple myeloma. Expand
Antitumor activity of thalidomide in refractory multiple myeloma.
TLDR
Thalidomide can induce marked and durable responses in some patients with multiple myeloma, including those who relapse after high-dose chemotherapy, and is active against advancedMyeloma. Expand
...
1
2
3
...